209 related articles for article (PubMed ID: 22134132)
1. Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid β monoclonal antibody solanezumab in Japanese and white patients with mild to moderate alzheimer disease.
Uenaka K; Nakano M; Willis BA; Friedrich S; Ferguson-Sells L; Dean RA; Ieiri I; Siemers ER
Clin Neuropharmacol; 2012; 35(1):25-9. PubMed ID: 22134132
[TBL] [Abstract][Full Text] [Related]
2. Validation of assays for measurement of amyloid-β peptides in cerebrospinal fluid and plasma specimens from patients with Alzheimer's disease treated with solanezumab.
Lachno DR; Evert BA; Vanderstichele H; Robertson M; Demattos RB; Konrad RJ; Talbot JA; Racke MM; Dean RA
J Alzheimers Dis; 2013; 34(4):897-910. PubMed ID: 23302661
[TBL] [Abstract][Full Text] [Related]
3. Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.
Siemers ER; Friedrich S; Dean RA; Gonzales CR; Farlow MR; Paul SM; Demattos RB
Clin Neuropharmacol; 2010; 33(2):67-73. PubMed ID: 20375655
[TBL] [Abstract][Full Text] [Related]
4. First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease.
Delnomdedieu M; Duvvuri S; Li DJ; Atassi N; Lu M; Brashear HR; Liu E; Ness S; Kupiec JW
Alzheimers Res Ther; 2016 Mar; 8(1):12. PubMed ID: 26925577
[TBL] [Abstract][Full Text] [Related]
5. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease.
Farlow M; Arnold SE; van Dyck CH; Aisen PS; Snider BJ; Porsteinsson AP; Friedrich S; Dean RA; Gonzales C; Sethuraman G; DeMattos RB; Mohs R; Paul SM; Siemers ER
Alzheimers Dement; 2012 Jul; 8(4):261-71. PubMed ID: 22672770
[TBL] [Abstract][Full Text] [Related]
6. Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N‑truncated Abeta in sporadic Alzheimer disease cases and mouse models.
Bouter Y; Lopez Noguerola JS; Tucholla P; Crespi GA; Parker MW; Wiltfang J; Miles LA; Bayer TA
Acta Neuropathol; 2015 Nov; 130(5):713-29. PubMed ID: 26467270
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
[TBL] [Abstract][Full Text] [Related]
8. Solanezumab for the treatment of mild-to-moderate Alzheimer's disease.
Imbimbo BP; Ottonello S; Frisardi V; Solfrizzi V; Greco A; Seripa D; Pilotto A; Panza F
Expert Rev Clin Immunol; 2012 Feb; 8(2):135-49. PubMed ID: 22288451
[TBL] [Abstract][Full Text] [Related]
9. Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease.
Honig LS; Vellas B; Woodward M; Boada M; Bullock R; Borrie M; Hager K; Andreasen N; Scarpini E; Liu-Seifert H; Case M; Dean RA; Hake A; Sundell K; Poole Hoffmann V; Carlson C; Khanna R; Mintun M; DeMattos R; Selzler KJ; Siemers E
N Engl J Med; 2018 Jan; 378(4):321-330. PubMed ID: 29365294
[TBL] [Abstract][Full Text] [Related]
10. Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients.
Siemers ER; Sundell KL; Carlson C; Case M; Sethuraman G; Liu-Seifert H; Dowsett SA; Pontecorvo MJ; Dean RA; Demattos R
Alzheimers Dement; 2016 Feb; 12(2):110-120. PubMed ID: 26238576
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer's disease.
Yoshida K; Moein A; Bittner T; Ostrowitzki S; Lin H; Honigberg L; Jin JY; Quartino A
Alzheimers Res Ther; 2020 Jan; 12(1):16. PubMed ID: 31969177
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody.
Logovinsky V; Satlin A; Lai R; Swanson C; Kaplow J; Osswald G; Basun H; Lannfelt L
Alzheimers Res Ther; 2016 Apr; 8(1):14. PubMed ID: 27048170
[TBL] [Abstract][Full Text] [Related]
13. Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.
Landen JW; Zhao Q; Cohen S; Borrie M; Woodward M; Billing CB; Bales K; Alvey C; McCush F; Yang J; Kupiec JW; Bednar MM
Clin Neuropharmacol; 2013; 36(1):14-23. PubMed ID: 23334070
[TBL] [Abstract][Full Text] [Related]
14. Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?
Panza F; Solfrizzi V; Imbimbo BP; Logroscino G
Expert Opin Biol Ther; 2014 Oct; 14(10):1465-76. PubMed ID: 24981190
[TBL] [Abstract][Full Text] [Related]
15. Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimer's disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study.
Miyoshi I; Fujimoto Y; Yamada M; Abe S; Zhao Q; Cronenberger C; Togo K; Ishibashi T; Bednar MM; Kupiec JW; Binneman B
Int J Clin Pharmacol Ther; 2013 Dec; 51(12):911-23. PubMed ID: 24131736
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled study.
Timmers M; Streffer JR; Russu A; Tominaga Y; Shimizu H; Shiraishi A; Tatikola K; Smekens P; Börjesson-Hanson A; Andreasen N; Matias-Guiu J; Baquero M; Boada M; Tesseur I; Tritsmans L; Van Nueten L; Engelborghs S
Alzheimers Res Ther; 2018 Aug; 10(1):85. PubMed ID: 30134967
[TBL] [Abstract][Full Text] [Related]
17. Lessons learned from the failure of solanezumab as a prospective treatment strategy for Alzheimer's disease.
Lozupone M; Dibello V; Sardone R; Castellana F; Zupo R; Lampignano L; Bortone I; Stallone R; Altamura M; Bellomo A; Daniele A; Solfrizzi V; Panza F
Expert Opin Drug Discov; 2024 Jun; 19(6):639-647. PubMed ID: 38685682
[TBL] [Abstract][Full Text] [Related]
18. [Immunotherapy for Alzheimer's disease].
Falkentoft AC; Hasselbalch SG
Ugeskr Laeger; 2016 Jan; 178(3):V07150588. PubMed ID: 26815584
[TBL] [Abstract][Full Text] [Related]
19. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.
Doody RS; Thomas RG; Farlow M; Iwatsubo T; Vellas B; Joffe S; Kieburtz K; Raman R; Sun X; Aisen PS; Siemers E; Liu-Seifert H; Mohs R; ;
N Engl J Med; 2014 Jan; 370(4):311-21. PubMed ID: 24450890
[TBL] [Abstract][Full Text] [Related]
20. Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease.
Burstein AH; Zhao Q; Ross J; Styren S; Landen JW; Ma WW; McCush F; Alvey C; Kupiec JW; Bednar MM
Clin Neuropharmacol; 2013; 36(1):8-13. PubMed ID: 23334069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
